Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly's new U.S. facility will be just the first of four that it plans to build in the country. The company expects to ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...